ClinicalTrials.gg
Enrolling by invitationNCT07825129Updated Sep 17, 2026

Disposable Intestinal Isolation and Protection Device for Patients With Rectal and Lower Sigmoid Colon Tumors Undergoing Laparoscopic AR/LAR Surgery

An interventional study of According to the different structures, it is divided into TPYRIB type and TPYRIS type. According to the different outer dimensions of the pocket and the outer sleeve, it is divided into two specificat and sterile gauze in Disposable Intestinal Isolation and Protection Device, sponsored by Beijing Friendship Hospital. Enrolling by invitation at 1 site in China. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Beijing Friendship Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
22 Years and older
Sex
All
01

Study summary

The small intestine is the main organ in the abdominal cavity, approximately 4 to 5 meters in length, occupying most of the middle and lower abdomen. Due to the long mesentery of the small intestine, it is in a free state and has a high degree of mobility. When performing abdominal surgery, especially lower abdominal surgery, the freedom and slippability of the small intestine often affect the exposure of the surgical site and the operating field of vision. Lower abdominal surgery generally includes colorectal surgery, gynecological surgery, urological surgery, etc. At present, in clinical practice, open surgeries, including minimally invasive laparoscopic manual surgeries, mainly involve significantly adjusting the patient's position to slide the small intestine into the surgical field, or simply surrounding and covering the small intestine with gauze pads and assisting in pulling with the help of assistants. However, the results are not satisfactory, especially for obese patients.

In the current clinical practice of performing middle and lower abdominal surgeries, especially laparoscopic surgeries, a device superior to gauze isolation pads is needed. It can separate the small intestine from the surgical site to expose the surgical area, facilitating doctors to perform manual operations calmly and reducing the operation time and complications. Avoid the special position with the head low and the feet high, which may increase the risk of restricted cardiac and respiratory functions in patients and reduce the impact on surgical anesthesia.

To collect more data on the efficacy and safety of this product for abdominal surgery, it is planned to conduct this post-market clinical study. This clinical study will adhere to the Good Clinical Practice for Medical Devices and relevant laws and regulations, and strictly implement the clinical research protocol.

02

Conditions studied

  • Disposable Intestinal Isolation and Protection Device
03

In context

Lead sponsor

Beijing Friendship Hospital is the lead sponsor of 217 studies on the registry; 94 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥22 years old, gender not limited.
  • Patients with rectal and lower sigmoid colon tumors who underwent laparoscopic AR/LAR surgery.
  • Patients with a of ≥25 agreed to participate in this trial and signed the form.
  • The distance between the tumor and the anus as measured by enteroscopy should not exceed 20cm.

Exclusion criteria

Exclusion Criteria:

  • Female patients who have participated in or are currently participating in other clinical studies within 3 months before the operation,
  • Have acute infections,
  • Severe small intestinal adhesions or severe edema,
  • Severe abdominal adhesions,
  • Are known to be allergic to silicone,
  • Have a history of severe allergies or severe immune deficiencies,
  • Are pregnant or lactating.
  • The researcher judged that the patient had poor compliance and was unable to complete the study as required.
  • Due to cognitive impairment, I am unable to understand the researcher's introduction or explanation of this trial.
  • Those who have undergone previous intestinal or pelvic surgery.
  • Tissues removed during surgery, including those with sharp or pointed edges, such as broken bone fragments, are not suitable for use with this instrument.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
140 participants (estimated)

Study arms

  • Active comparator
    Conventional gauze group

    Conventional surgery method

    Device: sterile gauze

  • Experimental
    Intestinal devrce group

    Operate using specialized equipment

    Device: According to the different structures, it is divided into TPYRIB type and TPYRIS type. According to the different outer dimensions of the pocket and the outer sleeve, it is divided into two specificat

Interventions

  • DeviceAccording to the different structures, it is divided into TPYRIB type and TPYRIS type. According to the different outer dimensions of the pocket and the outer sleeve, it is divided into two specificat

    The TPYRIB type is composed of a separator bag, a binding film, a tightening sleeve, a push rod handle, a push rod, an outer sleeve, an outer sleeve handle, a hook and a spring clip, a puncture needle, a fixing plate and a pull hook. The TPYRIS type is composed of an outer sleeve cap, a spacer bag, an expansion ring, a pull rod, a push rod handle, a push rod, an outer sleeve, an outer sleeve handle, a hook and a retaining ring, and a fixed block.

  • Devicesterile gauze

    sterile gauze

06

What researchers measure

Primary outcomes

  1. The main efficacy evaluation index: During the surgery.

    Evaluation method: Treatment group: The time from opening and starting to use the disposable small intestinal isolation protection device to completing the retrieval of the disposable small intestinal isolation bag. Control group: From the first time the gauze is opened and used to the time when the last piece of gauze is retrieved.

    Time frame: The subject visit windows are set as follows: Screening period: -7 days, i.e., within 7 days before the surgery Treatment period: 0 days, on the day of the surgery Observation period: 1-7 days after the surgery (including 7 days after the surgery) Follow

Secondary outcomes

  1. Evaluation of equipment usage

    On the day of the surgery (within 24 hours), the researchers evaluated the ease of use of the product during open surgery and laparoscopic surgery, whether there was accidental injury to surrounding organs, whether the surgical field was satisfactory, and whether multiple isolations were required. Use a 5-point scale (0 for light, 5 for heavy, in ascending order).

    Time frame: From the time of enrollment until the end of the 3-month treatment period.

  2. Surgical Position Record

    On the day of surgery (within 24h), the researcher adjusted the body position according to the intraoperative requirements, which was supine, within 15° (0-15° including 15°), 15-30 ° (15°-30° including 30°), and more than 30° (greater than 30°).

    Time frame: From the time of enrollment until the end of the 3-month treatment period.

  3. First exhaust time

    Starting from the day of the surgery, record the duration (eg. 12h-24 m, HH-MM) of the first time the patient passed gas after the surgery.

    Time frame: From the time of enrollment until the end of the 3-month treatment period.

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2026 (actual). Primary completion is estimated for Nov 2027, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2026
First posted
Sep 17, 2026
StartActual
May 27, 2026
Primary completionEst.
Nov 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07825129
Responsible party
Zhongtao Zhang (professor, Beijing Friendship Hospital) — Principal investigator
First posted
Sep 17, 2026
Start date
May 27, 2026
Primary completion
Nov 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Sep 17, 2026

Study contacts

ZHONGTAO ZHANG, Doctor
study chair · Beijing Friendship Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion